Glycovax Pharma commercializes a more affordable CRM197 protein

Montreal, Canada, June 9, 2025 – Glycovax Pharma Inc. has begun large-scale biomanufacturing of the CRM197 protein for use in numerous conjugate vaccines for human and animal vaccines. The National Research Council of Canada (NRC) has developed a unique and highly efficient production system for CRM197. Glycovax has refined its production to meet regulatory requirements at levels that exceed the quality standards for conjugate vaccine components for human and animal administration. Glycovax Pharma will market this protein through its subsidiary Espoir Therapeutics Inc. to meet the needs of vaccine development companies and research centers in the sector.

Carbohydrate-based vaccines are one of the most important medical innovations of the last century, having saved millions of lives from bacterial infections worldwide. To date, only a handful of proteins have been used in conjugate vaccines, CRM197 being the most widely used due to its invaluable properties. Despite its important role, large-scale production of CRM197 at reasonable cost has been a limitation for vaccine developers. Glycovax Pharma aims to make the protein more accessible to vaccine developers to better protect the health of populations.

“This agreement with the NRC marks an important milestone for our company,” said Dany Valiquette, President and CEO of Glycovax Pharma. “Over the next few months, we will be able to offer CRM197 to vaccine developers, whether pharmaceutical, biotech companies or university research institutions, guaranteeing them a large-scale, cost-effective, GMP-compliant manufacturing process. These developers will have the opportunity to evaluate our CRM197 with their own antigens, and Glycovax will support them in the regulatory aspects of their vaccine development.”